A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with letrozole versus letrozole alone in post-menopausal women with recurrent, oestrogen and/or progesterone receptor positive breast cancer
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Tiomolibdate choline (Primary) ; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2017 New trial record